U.S. regulators on Monday approved a pill version of the blockbuster weight-loss drug Wegovy<\/a>, marking the first time a daily oral medication has been green-lit to treat obesity. <\/p>\n The change is expected to drive even further adoption of the already widely popular GLP-1 class of drugs<\/a> and help fight chronic obesity around the world. <\/p>\n \u201cWe now have injectable-like efficacy in a once-daily pill,\u201d David Moore, executive vice president of Wegovy maker Novo Nordisk\u2019s U.S. operations, told<\/a> The Wall Street Journal. \u201cAnd that\u2019s a change from where we\u2019ve been in terms of treating obesity.\u201d<\/p>\n GLP-1 drugs such as Wegovy<\/a>, which also comes in an injectable form, mimic a natural hormone that controls appetite and feelings of fullness.<\/p>\n The Food and Drug Administration<\/a>\u2019s approval of the Wegovy pill is expected to help drive further use of such drugs, which some have avoided due to the higher cost of injections, which can be priced at upwards of $1,000 per month, as well as issues with insurance and fear of needles.<\/p>\n open image in gallery<\/p>\n The Food and Drug Administration on Monday gave the green light to Novo Nordisk\u2019s Wegovy pill, the first time an oral GLP-1 treatment has been approved, a development expected to expand access to the blockbuster category of weight-loss drugs (Copyright 2018 The Associated Press. All rights reserved.)<\/p>\n \u201cThis is a meaningful step forward in the field,\u201d Dr. Christopher McGowan, a gastroenterologist who runs a weight loss clinic in Cary, North Carolina, told<\/a> NBC News. \u201cIt won\u2019t replace injectables, but it broadens our tool kit in an important way.\u201d<\/p>\n \u201cPills are familiar, non-intimidating and fit more naturally into most people\u2019s routines,\u201d he added. \u201cFor many patients, a pill isn\u2019t just easier, it\u2019s psychologically more acceptable.\u201d<\/p>\n Last month, the Trump administration announced a deal with Novo Nordisk<\/a> to offer starting doses of the Wegovy pill for $149 a month. Now that the medication has been approved, it is expected to go to market in the coming weeks.<\/p>\n The Novo Nordisk obesity pill contains 25 milligrams of semaglutide. That’s the same ingredient in injectables such as Wegovy and Ozempic, as well as Rybelsus, a lower-dose pill approved to treat diabetes in 2019.<\/p>\n open image in gallery<\/p>\n The Wegovy pill is expected to generate sales of nearly $2 billion in 2030 for drugmaker Novo Nordisk, according to analysts (AFP\/Getty)<\/p>\n In a clinical trial, participants who took oral Wegovy lost 13.6 percent of their total body weight on average over about 15 months, compared with a 2.2 percent loss if they took a placebo, or dummy pill. That\u2019s nearly the same as injectable Wegovy, whose patients saw an average weight loss of about 15 percent.<\/p>\n Chris Mertens, 35, a pediatric lung doctor in Menomonee Falls, Wisconsin<\/a>, joined a Novo Nordisk trial in 2022 and lost about 40 pounds using the Wegovy pill. The daily medication worked to decrease his appetite and invasive thoughts of food, he told The Associated Press. <\/p>\n \u201cIf there were days where I missed a meal, I almost didn\u2019t realize it,\u201d Mertens said.<\/p>\n Dr. David Kessler, a former commission of the FDA, warned in an interview with The New York Times that these results will need to be validated in the real world.<\/p>\n open image in gallery<\/p>\n GLP-1 drugs tackle obesity by mimicking hormones that control the appetite and feelings of fullness (Getty Images)<\/p>\n \u201cWhat we\u2019re learning is the actual effectiveness of these drugs really are going to need to be determined by real-world evidence,\u201d he told<\/a> the paper. \u201cTrials always look better than they are in practice.\u201d<\/p>\n In recent years, Novo Nordisk\u2019s injectable Wegovy and Lilly\u2019s Zepbound have revolutionized obesity treatment globally and in the U.S., where 100 million people have the chronic disease.<\/p>\n About 1 in 8 Americans<\/a> have used injectable GLP-1 drugs, according to a survey from KFF, a nonprofit health policy research group. <\/p>\n The Wegovy pill is expected to generate sales of nearly $2 billion in 2030, according to analysts from TD Cowen.<\/p>\n open image in gallery<\/p>\n GLP-1 pills are expected to broaden access to such treatments, given that their injectable form can cost upwards of $1,000 per month (AP)<\/p>\n Novo Nordisk<\/a> rival Eli Lilly<\/a> has a pending obesity pill of its own, orforglipron, which is still under review.<\/p>\n The company, which manufactures competitor drugs to Wegovy including Zepbound and Mounjaro, is expected to get approval sometime around March.<\/p>\n","protected":false},"excerpt":{"rendered":"Your support helps us to tell the story From reproductive rights to climate change to Big Tech, The…\n","protected":false},"author":2,"featured_media":650892,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[105,4326,16,15],"class_list":{"0":"post-650891","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-uk","11":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115770337495216363","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/650891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=650891"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/650891\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/650892"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=650891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=650891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=650891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![\"The](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/12\/Obesity_Pill_72947.jpg\")
<\/p>\n![\"The](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/12\/GettyImages-2245790046.jpg\")
<\/p>\n![\"GLP-1](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/11\/GettyImages-2150033203.jpg\")
<\/p>\n![\"GLP-1](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/12\/EEUU-OBESIDAD_58522.jpg\")
<\/p>\n